Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Developed by Eli Lilly, Tirzepatide combines the effects of two incretin hormones in a single molecule. The dual agonism provides synergistic effects on insulin secretion, glucagon suppression, and appetite regulation. Clinical trials demonstrated superior glycemic control compared to existing diabetes medications and remarkable weight loss (up to 22.5% in the SURMOUNT trials). Tirzepatide represents a paradigm shift in metabolic disease treatment through its innovative multi-receptor approach.
| Research Status | FDA approved |
|---|---|
| Half-Life | ~5 days |
| Administration | Subcutaneous injection |
| Typical Dosage | 2.5-15 mg weekly |
| Molecular Weight | 4,813.5 Da |
| Molecular Formula | C225H348N48O68 |
Activates both GIP and GLP-1 receptors for enhanced metabolic effects and greater weight loss.
All information is presented for Research Use Only (RUO). Not medical advice.